Oncolytic adenoviruses, also called conditionally replicating adenoviruses (CRADs), have been widely applied in cancer gene therapy. However, the construction of CRADs is still time-consuming. In this study, we attempted to establish a simplified method of generating CRADs based on AdEasy system. A novel plasmid pTE-TPE-GM was constructed, containing sequentially positioned promoter of telomerase reverse transcriptase (TERTp), coding sequence of E1A gene, promoter of E1B gene, granulocytemacrophage colony-stimulating factor (GM-CSF) gene, internal ribosome entry site sequence and coding sequence of E1B55K gene. The CRAD-generating system reported here include three plasmids: pTE-TPE-GM, pShuttle-CMV and AdEasy-1, one Escherichia coli strain BJ5183, and the packaging cell line 293. Using this system, an oncolytic adenovirus carrying B7-1 (CD80) and GM-CSF genes was successfully constructed and designated as Ad-CD80-TPE-GM. The expression of GM-CSF increased more than 9000 times in tumor cell lines infected by Ad-CD80-TPE-GM at a multiplicity of infection (MOI) of 5, compared with the cells infected by replication-defective control virus. Similarly, the expression of CD80 also increased 9-140 times. Ad-CD80-TPE-GM selectively replicates in TERT-positive tumor cells, and the progeny viruses can reach up to 375 infection units (IU) per cell. In vitro study showed that the Ad-CD80-TPE-GM induced an obvious oncolytic effect at MOI of 0.1, and killed about 80% TERT-positive tumor cells within 7 days at an MOI of 1. The antitumor effect of this vector was also investigated in Hep2 xenograft model of nude mice, and the tumor inhibition rate reached 74% at day 30 after the administration with a total dose of 1 Â 10 9 IU Ad-CD80-TPE-GM.
Introduction
Cancer gene therapy represents a novel treatment approach for patients resistant to traditional therapies. Adenoviruses (Ads) are widely applied in cancer gene therapy due to their advantages over other vectors, such as effective gene delivery and expression, the ability to transduce both dividing and nondividing cells, the ease of manipulation and the capability to produce high titers of current good manufacturing practice quality. 1 Traditional replication-defective Ad vectors, which are deleted in E1 or together with E3 region and usually propagated in E1-transformed 293 cells, can not replicate and express their genomes to produce progeny viruses in other cells after infection, due to the absence of viral E1 proteins.
This property contributes to the safety of traditional Ad vectors. However, the clinical outcome is discouraging, 2 because such viruses could hardly penetrate whole tumor tissues, thereby reach and enter every tumor cell in vivo. This results in the low gene transfer rate and low transgene expression. To overcome this hurdle, the concept of oncolytic adenovirus was brought forward a decade ago. 3 Oncolytic Ads, also called conditionally replicating Ads (CRADs), can selectively propagate in and then lyse tumor cells, and the released progeny viruses can again infect the neighboring cancer cells. The cascade response proceeds, and tumor is destroyed in the end. When CRADs reach and infect normal cells, the viral replication process stops, therefore, it is safe for normal cells. Prototypes of CRADs, such as ONYX-015, 3 carry no transgenes. They only possess the ability of spreading among tumor cells. Later, it is recognized that CRADs bearing therapeutic gene may lyse tumor more effectively. Therapeutic gene can spread along with the dissemination of CRADs. Moreover, the copy number of transgene increases very significantly, as a result of replication of viral genome in CRAD-infected cancer cells. All these factors contribute to more efficient expression of transgene carried by CRAD, compared with traditional replication-incompetent virus. Now, it is widely accepted that CRAD should be combined with transgene. 4 Two strategies have been used to construct oncolytic Ads. 1, 5 One strategy is to construct genetic complementation-type (type 1) CRADs, such as ONYX-015. These CRADs contain mutation(s) in key viral gene(s), which can be complemented in tumor cells but not in normal cells. The other strategy is to construct transcomplementation-type (type 2) CRADs, also called transcriptionally regulated oncolytic Ads. The viral replication is restricted in tumor cells by placing tumor/tissue-specific promoter(s) (TSP) in front of key viral transcription unit(s).
Since the first clinical trial of oncolytic adenovirus ONYX-015 in 1996, 3 a number of CRADs have been constructed. The majority of these CRADs were rescued by homologous recombination of shuttle and backbone plasmids in 293 cells. As for the detailed construction protocol, each research group usually has their own favorites, and there is no uniform rule to pursue. It is even more difficult to design and engineer a new CRAD for laboratories without experience in vector reconstruction. Since the establishment of AdEasy system in 1998, replication-incompetent Ad vector can be routinely used in gene function research. 6 The major improvement of AdEasy system is that, instead of eukaryotic 293 cells, the recombination between shuttle and backbone plasmids occurs in prokaryotic cell Escherichia coli, which is more efficient. As a result, the efficiency of recombination was greatly enhanced. Furthermore, the recombinant plasmid is homogeneous as extracted from a single bacterial colony. Therefore, the adenovirus generated in packaging cells after transfection with this plasmid is also homogeneous, indicating that plaque purification is dispensable. In this study, we attempted to establish an operable method of constructing CRADs based on AdEasy system, which is simple, controllable and time-saving. Construction of viruses Plasmid JM17 was a kind gift of Dr MING FAN (Beijing Institute of Basic Medical Sciences, Beijing 100850, China). Cloning plasmid pTE was a product selfcircularized of pGEM-T Easy vector (Promega, Madison, WI). Plasmid pIRESneo was from Clontech (Palo Alto, CA). AdEasy-1 backbone and pShuttle-CMV plasmids were from Stratagene (La Jolla, CA). Ad-p53/GM-CSF/ B7-1, 10 AdGFP 11 Ads, GT8020 (containing CD80 gene) and GT4138 (containing granulocyte-macrophage colony-stimulating factor gene, GM-CSF) plasmids were constructed previously or stored in our laboratory. All restriction enzymes, calf intestinal alkaline phosphatase and T4 DNA ligase were purchased from New England Biolabs (Beijing 100083, China). KOD-plus Taq enzyme (Toyobo, Shanghai, China) was used in PCR amplification. pJM17 was cut by PmlI, and then the 12 498 bp fragment, which contains E1 genes of Ad5, was selfrelegated to form a new plasmid called pJM13.
Materials and methods

Cell culture
The plasmid pTE-TPE-GM was constructed as follows: partial E1B55K gene (1891 bp) was excised from JM13 with KpnI and SmaI, termini-blunted and ligated to blunted NsiI site of pTE. The generated plasmid was called pTE-E1B55K. E1B55Kplus, IVS-IRES (synthetic intron-internal ribosome entry site), GM-CSF, E1A-E1Bp, telomerase reverse transcriptase promoter (TERTp) and SV40pA fragments were all amplified by PCR and added to pTE-E1B55K sequentially. PCR-related information and corresponding restriction sites used in the cutting and ligating operation are listed in Table 1. CD80 gene was excised from GT8020 with NcoI and BglII, termini-blunted and ligated with the blunted fragment of pShuttle-CMV cut by BglII and EcoRV to generate pShuttle-CD80. The 533 bp fragment between the two MfeI sites of pShuttle-CD80 was replaced by the corresponding 4133 bp fragment of pTE-TPE-GM. The generated shuttle plasmid was called as pSh-CD80-TPE-GM, which was used to recombine with backbone plasmid pAdEasy-1 to produce CRAD Ad-CD80-TPE-GM according to the manual of AdEasy system. 6 All fragments amplified with PCR method were verified by DNA sequencing.
All Ads were packaged in 293 cells, purified by double CsCl density gradient ultracentrifugation, dissolved in storage buffer (Hank's buffer, 10% glycerol) and stored at À80 1C. Viral particle (vp) numbers were calculated from measurements of optical density at 260 nm (OD 260 ), where one absorbency unit is equivalent to 1.1 Â 10 12 vp per milliliter, 12, 13 and infectious titers (infection units per milliliter, IU per ml) were determined by limiting dilution assay on 293 cells; 14 the multiplicity of infection (MOI) was calculated from infectious titers.
Gene expression assay Expression of E1B55K was determined by western blot. Briefly, PC3M cells were infected for 2 h by Ad-CD80-TPE-GM or control virus AdGFP at an MOI of 50. After 2 days of infection, cells were harvested and lysed for examination of E1B55K expression by western blot using anti-adenovirus 5 E1B55K rat monoclonal antibody (mAb) (clone 9C10; Calbiochem, San Diego, CA).
Expression of GM-CSF was analyzed with enzymelinked immunosorbent assay (ELISA). Cells (1 Â 10 5 ) were infected with Ad-CD80-TPE-GM or Ad-p53/ GM-CSF/B7-1 at an MOI of 5 in 24-well plate, and 2 h later, viruses were removed. After 48 h of infection, the supernatant was collected and tested for GM-CSF by ELISA (catalog DY215; R&D Systems, MN). Serial dilutions of the known concentration of purified recombinant human GM-CSF were used to establish a standard curve.
Expression of CD80 was analyzed with flow cytometry. Cells 
Cell viability assay
Exponentially growing cells were seeded at a density of 3 Â 10 4 cells per well in 96-well plates and infected 24 h later with Ad-CD80-TPE-GM or AdGFP in 60 ml culture media per well at serial MOIs. After 3 days of infection, 100 ml fresh culture media was supplemented to each well. At day 7 postinfection, cells were fixed in 1% glutaraldehyde (v/v) in PBS for 30 min before stained with 0.1% crystal violet (w/v) in water. After washing, crystal violet dye was dissolved from cells by 2 h rotary incubation at 25 1C with 1% Triton X-100 (v/v) in water. Absorbance of the resulting Triton extract was read at 570 nm on a microplate reader. Cell survival rate is absorbance of tested well normalized by that of uninfected control well.
Virus replication in vitro
Exponentially growing cells were seeded at a density of 1 Â 10 5 cells per well in 24-well plates and infected 24 h later with Ad-CD80-TPE-GM at an MOI of 5. After incubation for 2 h, viruses were removed by rinsing twice with culture media without FBS, and then 500 ml of fresh media was added to each well. Cells were collected and combined with culture supernatant 24, 48, 72 or 96 h 
Length of PCR product (bp)
Restriction enzyme
Abbreviations: E1A-E1Bp, E1A gene-E1B promoter; GM-CSF, granulocyte-macrophage colony-stimulating factor; IVS-IRES, synthetic intron-internal ribosome entry site of the encephalomyocarditis virus; SV40pA, SV40 ployA signal; TERTp, telomerase reverse transcriptase promoter.
'F' and 'R' in the primers column represent forward and reverse primers, respectively. '-' represents none.
postinfection. Lysates were prepared by three cycles of freeze-and-thaw and used to determine virus titer by limiting dilution assay on 293 cells. 14 
Animal experiments
Exponentially growing Hep2 cells were subcutaneously injected into the right flanks of male BALB/c nude mice each with 2 Â 10 6 cells suspended in 100 ml PBS. When tumors reached about 70 mm 3 in volume, mice were allotted randomly into two groups: Ad-CD80-TPE-GM and control groups. Each group consisted of six mice. Daily intratumoral injections of Ad-CD80-TPE-GM (2 Â 10 8 IU in 100 ml PBS) were administered for mice in tested group during 5 consecutive days. The total dose was 10 9 IU per mouse. The control animals were injected with PBS alone. Tumor size was monitored regularly by measuring length and width with a caliper. Tumor volume was calculated with the following formula: width 2 Â length/2. Mice were killed at day 30 posttreatment (day 0 was when the first intratumoral injection occurred), and tumor tissues were removed and weighed. All procedures were performed following the local guideline for animal care.
Anti-adenovirus neutralizing antibody assay Nude mice were planted with Hep2 cells, followed by intratumoral administration of Ad-CD80-TPE-GM or PBS just as described above. At days 9, 18 and 39 after the first injection of virus, serum samples were collected from the tail veins for titration of the anti-adenovirus neutralizing antibody (Nab). Hep2 cells were seeded in 96-well plates in 0.1 ml complete medium. Nude mice serum samples were incubated for 30 min at 56 1C to inactivate complement, and then were serially diluted in complete medium before thoroughly mixed with 4 Â 10 6 IU of Ad-CD80-TPE-GM. Following a 1 h incubation at room temperature, medium was aspirated from the confluent monolayers of Hep2 cells and replaced with 0.1 ml of the serum/virus mixture. Following a 2-day incubation at 37 1C, cell death was measured by crystal violet staining as mentioned in the 'Cell viability assay' section. The highest dilution of serum at which cell viability was above 50% as determined by crystal violet intensity was designated the neutralizing titer. 15 
Statistical analysis
The data were presented as mean±s.d. (standard deviation). Nonparameter rank-sum test was used to analyze the activity of NAbs. Student's t-test was carried out to assess the statistical difference of other data. Po0.05 was considered to be significant.
Results
Generation of CRAD Ad-CD80-TPE-GM
In this study, we aimed to establish a simplified system to generate CRAD by homologous recombination in E. coli. For this purpose, a plasmid containing E1 genes of Ad5 should be constructed in addition to the shuttle and , tumor cell-specific promoter (i.e. promoter of telomerase reverse transcriptase, TERTp), E1 region of Ad5 without E1A promoter (E1) and partial right arm homolog (R arm) were inserted orderly in cloning plasmid pTE to form a new plasmid named pTE-TPE1. E1 region could be modified relatively easily in pTE-TPE1. Modified E1 was then excised from the plasmid with MfeI and substituted for the corresponding region between MfeI sites of pShuttle-CMV. The new shuttle plasmid (pShuttle-TPE1) could be used to generate oncolytic adenovirus according to standard procedure of AdEasy system. (b) Schematic diagram of the construction of pSh-CD80-TPE-GM plasmid. The detail is described in the 'Materials and methods' section. Human CD80 (B7-1) gene was inserted to multiple cloning sites (MCS) of pShuttle-CMV first, and then modified E1 region was integrated in the joint site between polyA signal and right arm homolog of pShuttle-CMV. (c) Schematic diagram of the oncolytic adenovirus Ad-CD80-TPE-GM, which was generated by recombination of pSh-CD80-TPE-GM and backbone plasmid pAdEasy-1 in BJ5183. Shown are the inverted terminal repeat (ITR), encapsidation signal (ES), CMV promoter (CMVp), E1B promoter (E1Bp), granulocyte-macrophage colony-stimulating factor gene (GM-CSF), internal ribosome entry site (IRES) of the encephalomyocarditis virus, kanamycin resistance ORF (Kan), pBR322 origin of replication (pBR322 ori) and left arm homolog (L arm). Also shown are the digestion sites of restriction enzyme MfeI and PacI.
backbone plasmids in AdEasy system. A prototype of this new plasmid, called pTE-TPE1, is illustrated in Figure 1a . Plasmid pTE-TPE1 is expected to have three characteristics: first, it should carry E1 genes, which can be reconstructed in order for the generated CRAD to replicate selectively in tumor cells; second, it should be small, thus the modification of E1 genes can be easily carried out; finally, modified E1 region can be excised and conveniently inserted into the proper site of shuttle plasmid. As shown in Figure 1a , pTE-TPE1 meets all these requisites: it contains all E1 genes except E1A promoter, which is replaced by TSP (TERTp, as an example); it contains a relatively small genome of about 6 900 bp; the modified E1 region can be precisely integrated in the joint point between SV40 ployA signal and the right homologous arm of pShuttle-CMV and this will transfer the modified E1 region back to the genome of future CRAD.
Based on the prototype, a pTE-TPE-GM plasmid was designed and constructed as described in the 'Materials and methods' section. In pTE-TPE-GM, E1 genes were reconstructed as following: E1A promoter was replaced by core sequence of TERTp, resulting in the generated CRAD propagates selectively in TERT-positive tumor cells; a gene of interest, GM-CSF, was introduced downstream of E1B promoter (E1Bp), while the E1B19K coding sequence in front of the start codon of E1B55K was totally deleted; the expression of E1B55K was controlled by IVS-IRES (of the encephalomyocarditis virus) between GM-CSF and E1B55K genes. Another transgene, CD80, was inserted to the multiple cloning sites (MCS) of pShuttle-CMV. The final shuttle plasmid, pSh-CD80-TPE-GM, was constructed by further introducing the modified E1 region between MfeI sites of pTE-TPE-GM. The schema for construction of pSh-CD80-TPE-GM is shown in Figure 1b .
Using the shuttle plasmid pSh-CD80-TPE-GM, backbone plasmid AdEasy-1, and packaging cell line 293, oncolytic virus Ad-CD80-TPE-GM was successfully generated according to the standard procedure of AdEasy system. 6 Compared to wild-type Ad, Ad-CD80-TPE-GM has three special gene expression units: CMVp-controlled CD80, TERTp-controlled E1A and E1Bp-controlled GM-CSF that harbors an IRES-linked E1B55K (Figure 1c) . The controls in this study include: AdGFP, a replication-defective Ad carrying GFP gene; 11 and Adp53/GM-CSF/B7-1, 10 a replication-defective Ad carrying CD80, p53 and GM-CSF genes. In Ad-p53/GM-CSF/ B7-1, p53 gene is controlled by CMV promoter, which is followed by IRES-linked GM-CSF. The CD80 gene is under the control of Rous sarcoma virus promoter. 10 All viruses were purified and reached a titer of 4 Â 10 10 IU per ml for Ad-CD80-TPE-GM and AdGFP, and 5 Â 10 9 IU per ml for Ad-p53/GM-CSF/B7-1. Corresponding particle-to-IU ratios were 28, 23 and 43, respectively.
Function of Ad-CD80-TPE-GM
E1B55K is an important gene for viral replication. In Ad-CD80-TPE-GM-infected cells, it is transcribed together with GM-CSF gene under the control of E1B promoter. Its translation is driven by IRES sequence in the transcription unit. As shown in Figure 2a , the expression of E1B55K in Ad-CD80-TPE-GM-infected PC3M cells was confirmed by western blot, implicating a proper vector design.
The expression of GM-CSF transgene was determined by ELISA methods (Figure 2b ). For telomerase-positive tumor cell lines, 48 h after infection by Ad-CD80-TPE-GM at an MOI of 5, the secreted GM-CSF reached or exceeded 100 ng ml
À1
. The concentration of GM-CSF increased about 16 000-, 9000-and 37 000-fold for A549, HeLa and Hep2 cells, respectively, when compared with that secreted from corresponding cells infected by equivalent Ad-p53/GM-CSF/B7-1. For normal telomerase-negative BJ cells, when infected by Ad-CD80-TPE-GM or control Ad-p53/GM-CSF/B7-1, the concentration of GM-CSF in culture supernatants was 1400 or 4 pg ml
, respectively. The relatively low increase of GM-CSF expression in Ad-CD80-TPE-GM-infected BJ cells might result from the different promoters used to control GM-CSF gene in the two vectors and the leaky activity of TERTp.
The increase of CD80 on the surface of infected cells was evaluated by flow cytometry and expressed as relative fluorescence intensity, which was the ratio of the geometrical mean of fluorescence intensity in total cells of each sample to that of control (Figure 2c ). On all the tested tumor cell lines infected by Ad-p53/GM-CSF/B7-1 at an MOI of 5, the expression of CD80 could hardly be detected as the relative fluorescence was less than 1.3. On the contrary, the expression of CD80 expanded significantly after infection of Ad-CD80-TPE-GM, and the expansion degree ranged from 9.06 times for HT29 to 146 times for Hep2. On normal fibroblast cell line BJ, neither Ad-p53/GM-CSF/B7-1 nor Ad-CD80-TPE-GM at an MOI of 5 could significantly induce the expression of CD80.
In conclusion, E1B55K, GM-CSF and CD80 could be expressed selectively in TERT-positive cells after infection of Ad-CD80-TPE-GM. Moreover, the expression of the two transgenes, GM-CSF and CD80, reached a remarkably high level due to the viral replication and spread.
Oncolytic effect of Ad-CD80-TPE-GM
In order to further evaluate the function of Ad-CD80-TPE-GM on various cell lines, first the gene transduction efficiency of adenoviral vector was detected using GFP reporter gene. U2OS and HepG2 were relatively susceptible to the infection of Ad5, whereas BJ and HT29 were not. The expression of GFP was comparable among the rest of tested cell lines when infected by AdGFP at identical MOI ( Table 2) .
The oncolytic ability of Ad-CD80-TPE-GM was assessed on several cell lines by the crystal violet staining method. As shown in Figure 3 , Ad-CD80-TPE-GM had little effect on the viability of TERT-negative cell line BJ even at a high MOI of 100. Although it caused nearly 60% of the TERT-negative U2OS cells dead at an MOI of 10, this could be explained with the highest viral infection efficiency on these cells (Table 2 ). In fact, the oncolytic Ad did not affect the viability of U2OS at an MOI of 1, the dose over 20% cells were initially infected (data not shown). In contrast, for tested TERT-positive tumor cell lines, at day 7 postinfection, it caused about 80% cells dead at a low MOI of 1. For these tumor cells, the oncolytic effect of Ad-CD80-TPE-GM was considerably evident at an MOI of 0.1 and could be observed even at an MOI of 0.01 for some cell lines, such as LS180 and HT29.
Replication of Ad-CD80-TPE-GM
The selective replication feature of Ad-CD80-TPE-GM was also investigated. Human cell lines were infected by Ad-CD80-TPE-GM at an MOI of 5, and the progeny viruses produced 24, 48, 72 and 96 h after infection were harvested and titrated (Figure 4 ). For tested tumor cells, the increase of viral titer correlated with culture period, and the titer exceeded 100 IU per cell along with the occurrence of complete cytopathic effect (CPE) 72 h postinfection. The experiment ended at 72 h for tumor cells due to the occurrence of complete CPE. For normal cell line BJ, the increase of viral titer was also visible, however, the highest value was 0.5 IU per cell at 72 h, much lower than tumor cells. Furthermore, the titer decreased at 96 h (data not shown). It was probably because that the viral replication, which is due to leaky activity of TERTp, was too weak to lyse BJ cells for virus release. Viruses could not spread among BJ cells and had little chance to proliferate. CPE was not observed for BJ cells. These data further demonstrated that Ad-CD80-TPE-GM can specifically replicate in TERT-positive tumor cells.
Antitumor effect of Ad-CD80-TPE-GM in vivo
Based on previous study, Hep2 cells were selected to induce heterogenous tumors in nude mice. 10 As shown in Figure 5a , tumor volume continuously increased in control group, on the contrary, administration of Ad-CD80-TPE-GM dramatically inhibited the tumor growth. After 30 days of the first treatment, the mean tumor volume for control group increased from 72.07 to 429.2 mm 3 , nearly six times. Whereas for mice treated with Ad-CD80-TPE-GM at a total dose of 1 Â 10 9 IU, this parameter just slightly increased from 72.09 to 149.2 mm 3 , about two times. At the end point of the experiment, mice were killed, and tumor tissues were removed and weighed. The mean tumor weight was 0.381 g for control mice, almost four times of Ad-CD80-TPE-GM-treated mice (Figure 5b) . Difference between the two groups was statistically significant (P ¼ 0.001). These data showed that Ad-CD80-TPE-GM inhibited the growth of xenografts in nude mice.
Induction of neutralizing antibody after administration of Ad-CD80-TPE-GM in vivo Oncolytic Ads can inhibit tumor growth in nude mice model. However, they cannot kill all of the cancer cells, due to the elimination of CRADs from the body after a period of propagation. We assume that NAb plays a role in the process of virus exclusion considering the normal humoral immune response to T-independent antigen in nude mice. 16 Sera were collected at days 9, 18 and 39 after the administration with a total dose of 1 Â 10 9 IU Ad-CD80-TPE-GM and the titer of NAb was determined. Titer of positive control serum reached a high level of 1280 (data not shown), suggesting a proper experimental operation. However, the titer of majority test samples was less than the lowest dilution fold of 40 and could not be expressed as a numerical value. Therefore, we chose to directly display the neutralizing activity of serum with the value of Hep2 cell viability, after infected by 1:40 serum-incubated Ad-CD80-TPE-GM. As shown in Figure 6 , the activity of NAb increased and persisted till day 18, and then declined at day 39 in group treated with Ad-CD80-TPE-GM. On the contrary, the NAb in PBS group nearly maintained a background level during the examination. Difference between the two groups at day 9 or 18 was significant (Po0.05), when analyzed with the nonparameter rank-sum test. The results indicate that NAb can be induced in nude mice after the administration of CRADs, which may contribute to virus clearance. Figure 3 Oncolytic effect of Ad-CD80-TPE-GM on human tumor cells. Cells cultured in 96-well plates were infected by Ad-CD80-TPE-GM or control replication-defective adenovirus AdGFP at serial multiplicity of infection (MOI), and cell survival rate was determined with crystal violet staining method 7 days postinfection. Ad-CD80-TPE-GM nearly did no harm to normal human cell line BJ at a high MOI as 100, whereas it caused about 80% tested tumor cells dead at a low MOI of 1. 
Discussion
Currently, cancer gene therapy focuses on oncolytic viruses. [17] [18] [19] A number of CRAD vectors have been constructed since the first clinical trial in 1996, in which a CRAD called ONYX-015 was administered to cancer patients. 3 Till now, the generation of CRADs is mainly through homologous recombination of shuttle and backbone plasmids in eukaryotic packaging cells, although replication-defective Ad vectors are commonly constructed by recombination in prokaryotic cell E. coli. In this study, we aim to establish a method of constructing CRADs based on AdEasy system, 6 in which the recombination of shuttle and backbone plasmids occurs effectively in E. coli.
Selective replication of CRADs can be realized by modification of pivotal regulation genes that are responsible for viral propagation. Replication-regulating genes are expressed mainly at early phase of viral life cycle, including the genes located in E1, E2, E3 and E4 regions. Among these genes, E3 products help viruses to escape from host's immune system 20 and are dispensable for viral replication. Oftentimes, E1 and E4 genes are exploited to target the replication of Ads to desired cells and tissues. 4 E1 region has more features or sites that can be employed to develop CRADs. Therefore, we chose to generate the third plasmid carrying E1 genes (Figure 1a ) in addition to the other two plasmids, pShuttle-CMV and AdEasy-1 in AdEasy system, to construct CRAD.
If the entire E1 region including E1A promoter is inserted into the third plasmid, either genetic complementation-type CRADs or transcriptionally regulated oncolytic Ads can be generated using the three plasmids system. Based on this, pTE-TPE-GM was constructed as the third plasmid, in which E1A promoter was replaced with TERTp, so that the new Ad can selectively replicate in TERTp-positive tumor cells. The E1B19K gene was also replaced with GM-CSF, a cytokine gene widely used in cancer gene therapy, and IRES sequence was introduced to drive the expression of downstream E1B55K. The second transgene CD80 was inserted into MCS of pShuttle-CMV to form pShuttle-CD80. In summary, three plasmids pTE-TPE-GM, pShuttle-CD80, AdEasy-1, one E. coli strain BJ5183 and one packaging cell line 293 constituted our CRAD construction system, to generate Ad-CD80-TPE-GM oncolytic vector.
Ad-CD80-TPE-GM has three special gene expression units: CMVp-controlled CD80, TERTp-controlled E1A and E1Bp-controlled GM-CSF, in which the downstream E1B55K is driven by IRES (Figure 1c) . TERTp, which is preferentially active in malignant cells, 21, 22 is used as Mean tumor weight of Ad-CD80-TPE-GM-infected group was significantly lower than that of the control (P ¼ 0.001), suggesting that Ad-CD80-TPE-GM could inhibit tumor growth in vivo. Figure 6 Anti-adenovirus neutralizing antibody (NAb) assay. Subcutaneous tumors were induced and treated as mentioned in the 'Materials and methods' section. NAb titer of majority samples was less than the lowest dilution fold of 40 and was hard to be displayed as a numerical value, so the cell viability of Hep2 treated with 1:40 serumincubated virus was chosen to represent the neutralizing ability of mice serum. The activity of NAb in CRAD-treated mice experienced an increase-and-then-decline process, while that in phosphatebuffered saline (PBS)-treated nearly maintained a background level. The difference of NAb activity between the two groups at day 9 or 18 was statistically significant when analyzed with the nonparameter rank-sum test (P ¼ 0.015 or 0.021, respectively).
TSP to control the expression of E1A. [23] [24] [25] Because the enhancer of E1A overlaps the inverted terminal repeat (ITR) sequence on the left, CMVp-controlled CD80 transcriptional unit was placed behind ITR to act as an insulator to minimize the enhancer effect on E1A. 26, 27 However, we still observed the leaky activity of TERTp as viral titer mildly increased in Ad-CD80-TPE-GM-infected BJ cells (Figure 4 ). This is because normal human fibroblasts express low levels of hTERT when undergoing cell division. 28 Moreover, the core sequence of TERTp used in this study does retain residual activity in TERT-negative cells. 29 Although efforts have been made to increase the specificity of TERTp, the result was not ideal. 29 The Bcl-2-like protein E1B19K, which can inhibit the apoptosis induced by viral infection in normal cells, 30 is dispensable for viral propagation in tumor cells. Furthermore, it has been showed that E1B19K deletion improves the ability of CRADs to kill cancer cells. [31] [32] [33] Therefore, E1B19K was deleted in our design. The expression of E1B55K is driven by upstream IRES sequence. In mRNA containing two coding frames linked by IRES (bicistron in eukaryotic cell), the downstream gene always expresses less. 34, 35 This is also the case for E1B55K in vector generated here. As seen in Figure 2a , in Ad-CD80-TPE-GM-infected PC3M cells, although there were multiple gene copies due to viral replication, the level of E1B55K expression was still lower than that in 293 cells carrying single active copy. 36 However, this level of expression was already enough for viral propagation as the yield of progeny viruses in tumor cells infected by Ad-CD80-TPE-GM was comparable to that produced in 293 cells (data not shown). GM-CSF and CD80 have definite function and have been widely used in cancer gene therapy. [37] [38] [39] Their therapeutic effect has been widely recognized, so we chose them as transgenes for our CRAD. The expression of GM-CSF and CD80 was greatly improved in tumor cells infected by Ad-CD80-TPE-GM, compared with cells infected by the control Ad (Figures 2b and c) . In the nude mice model, Ad-CD80-TPE-GM inhibited the growth of xenografts. Therefore, Ad-CD80-TPE-GM is a qualified CRAD and deserves further characterization.
A slight induction of anti-adenovirus NAb was observed in this study, suggesting a possible involvement of NAb in virus-clearance process in vivo. Tsai V et al. 40 reported an obvious titer enhancement of NAb after intravenous injection of CRADs in nude mice. The lower NAb titer in this study might be resulted from different administration manners of CRADs.
It is a system for generating CRAD bearing two transgenes, considering that TERTp, GM-CSF and CD80 can be replaced by other TSP or transgenes in this system. Although restriction sites for such substitution in pTE-TPE-GM are limited, precise design will help. Because the genome of Ad vector should not exceed approximately 105% the size of native genome, the total length of the three elements, including one TSP and two transgenes, must not exceed over 3200 bp. If GM-CSF and IRES sequence are deleted in pTE-TPE-GM, we will have a system to generate a transcription-regulated CRAD carrying only one transgene. The allowable total length of the insertion, including one TSP and one transgene, can extend up to 4500 bp.
Efforts are made to construct retargeting CRADs, 1 which combine all the properties such as conditional replication, transgene and retargeting. Fiber is the main ligand for Ad5 to enter cells. Previously, we have developed a method to generate retargeting Ad vector by modification of the fiber gene in AdEasy system.
11
Briefly, a small plasmid containing the whole fiber gene was separated from AdEasy-1 backbone plasmid, after fiber modification it could be easily integrated back to AdEasy-1. With this fiber-modified AdEasy-1 new retargeting Ad could be generated. Combining this small plasmid, pFiber5/11p, the system generated here will be able to be used to generate retargeting CRADs. The stability of CRADs is an important issue. 41 In the Ad-CD80-TPE-GM design, we have made efforts to maintain the genomic structure of this CRAD close to that of wild-type virus. Furthermore, different promoters were used to control expression of the two transgenes, which could avoid homologous recombination among identical sequences. Although we expect Ad-CD80-TPE-GM is stable, more studies have to be done.
In conclusion, we successfully constructed a TERTpcontrolled CRAD carrying GM-CSF and CD80 genes. And more importantly, this system is flexible and can be modified to generate novel transcriptionally regulated CRADs carrying other transgenes.
